The alliance will focus on providing glycotherapeutic products and services for research through to process scale-up and commercialization by way of an exclusive referral and co-marketing arrangement.
Commonwealth Biotechnologies (CBI), through its wholly owned subsidiary, Exelgen, will provide customers with research grade products and services, and New Zealand Pharmaceuticals (NZP) will supply customers with identified lead candidates for pre-clinical applications through to cGMP products for clinical and therapeutic applications. The CBI/NZP co-branded drug development services will be jointly marketed and promoted to the customer bases of both companies and to the broader pharmaceutical and biotechnology market.
Richard Garland, managing director of NZP, said: “The alliance is about enhancing the product offering of both companies by offering customers a full package of drug discovery, development and production services.”